Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 283

1.

A Phase 1 Trial of Intravesical Cabazitaxel, Gemcitabine, and Cisplatin for the Treatment of Non-muscle Invasive BCG Unresponsive or Recurrent/Relapsing Urothelial Carcinoma of the Bladder.

DeCastro GJ, Sui W, Pak JS, Lee SM, Holder D, Kates MM, Virk RK, Drake CG, Anderson CB, James B, Abate-Shen CT, McKiernan JM.

J Urol. 2020 Mar 2:101097JU0000000000000919. doi: 10.1097/JU.0000000000000919. [Epub ahead of print]

PMID:
32118506
2.

Establishing the inter-rater reliability of spinal cord damage manual measurement using magnetic resonance imaging.

Cummins DP, Connor JR, Heller KA, Hubert JS, Kates MJ, Wisniewski KR, Berliner JC, O'Dell DR, Elliott JM, Weber KA 2nd, Smith AC.

Spinal Cord Ser Cases. 2019 Feb 18;5(1):20. doi: 10.1038/s41394-019-0164-1.

PMID:
32066668
3.

Transcatheter aortic valve replacement 24 years after cardiac transplantation.

Wallen TJ, Spratt J, Kates MM, Wayangankar S, Vilaro J, Aranda J, Arnaoutakis GJ.

J Card Surg. 2020 Mar;35(3):710-712. doi: 10.1111/jocs.14438. Epub 2020 Jan 23.

PMID:
31971286
4.

Fungating Anal Mass: Extrapulmonary Small Cell Carcinoma Masquerading as a Hemorrhoid.

Kates MM, Goldstein LE, Thomas RM.

J Gastrointest Surg. 2019 Dec 17. doi: 10.1007/s11605-019-04498-1. [Epub ahead of print] No abstract available.

PMID:
31848872
5.

Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder Cancer.

Steinberg RL, Thomas LJ, Brooks N, Mott SL, Vitale A, Crump T, Rao MA, Daniels MJ, Wang J, Nagaraju S, DeWolf WC, Lamm DL, Kates M, Hyndman ME, Kamat AM, Bivalacqua TJ, Nepple KG, O'Donnell MA.

J Urol. 2019 Dec 10:101097JU0000000000000688. doi: 10.1097/JU.0000000000000688. [Epub ahead of print]

PMID:
31821066
6.

Reply by Authors.

Chappidi MR, Stimson CJ, Kates M, Odisho AY, Bivalacqua TJ.

J Urol. 2020 Mar;203(3):552-553. doi: 10.1097/JU.0000000000000522.03. Epub 2019 Nov 26. No abstract available.

PMID:
31769720
7.

Identification of Candidates for Salvage Therapy: The Past, Present, and Future of Defining Bacillus Calmette-Guérin Failure.

Becker REN, Kates MR, Bivalacqua TJ.

Urol Clin North Am. 2020 Feb;47(1):15-21. doi: 10.1016/j.ucl.2019.09.004. Review.

PMID:
31757296
8.

Adaptive Immune Resistance to Intravesical BCG in Non-Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive Trials.

Kates M, Matoso A, Choi W, Baras AS, Daniels MJ, Lombardo K, Brant A, Mikkilineni N, McConkey DJ, Kamat AM, Svatek RS, Porten SP, Meeks JJ, Lerner SP, Dinney CP, Black PC, McKiernan JM, Anderson C, Drake CG, Bivalacqua TJ.

Clin Cancer Res. 2020 Feb 15;26(4):882-891. doi: 10.1158/1078-0432.CCR-19-1920. Epub 2019 Nov 11.

PMID:
31712383
9.

Evaluation of Incisional Negative Pressure Wound Therapy in the Prevention of Surgical Site Occurrences After Radical Cystectomy: A New Addition to Enhanced Recovery After Surgery Protocol.

Joice GA, Tema G, Semerjian A, Gupta M, Bell M, Walker J, Kates M, Bivalacqua TJ.

Eur Urol Focus. 2019 Nov 5. pii: S2405-4569(19)30292-5. doi: 10.1016/j.euf.2019.09.016. [Epub ahead of print]

PMID:
31704281
10.

Impact of spheroid culture on molecular and functional characteristics of bladder cancer cell lines.

Yoshida T, Sopko NA, Kates M, Liu X, Joice G, Mcconkey DJ, Bivalacqua TJ.

Oncol Lett. 2019 Nov;18(5):4923-4929. doi: 10.3892/ol.2019.10786. Epub 2019 Aug 29.

11.

Circulating Tumor Cell and Circulating Tumor DNA Assays Reveal Complementary Information for Patients with Metastatic Urothelial Cancer.

Chalfin HJ, Glavaris SA, Gorin MA, Kates MR, Fong MH, Dong L, Matoso A, Bivalacqua TJ, Johnson MH, Pienta KJ, Hahn NM, McConkey DJ.

Eur Urol Oncol. 2019 Sep 25. pii: S2588-9311(19)30130-0. doi: 10.1016/j.euo.2019.08.004. [Epub ahead of print]

PMID:
31563523
12.

A Nationally Representative Study of Nonindex Hospital Readmissions following Radical Prostatectomy: Implications for Bundled Payment Models.

Chappidi MR, Stimson CJ, Kates M, Odisho AY, Bivalacqua TJ.

J Urol. 2020 Mar;203(3):546-553. doi: 10.1097/JU.0000000000000522. Epub 2019 Sep 3.

PMID:
31479405
13.

An evaluation of monthly maintenance therapy among patients receiving intravesical combination gemcitabine/docetaxel for nonmuscle-invasive bladder cancer.

Daniels MJ, Barry E, Milbar N, Schoenberg M, Bivalacqua TJ, Sankin A, Kates M.

Urol Oncol. 2020 Feb;38(2):40.e17-40.e24. doi: 10.1016/j.urolonc.2019.07.022. Epub 2019 Aug 28.

PMID:
31473090
14.

Optimizing pharmacokinetics of intravesical chemotherapy for bladder cancer.

Joice GA, Bivalacqua TJ, Kates M.

Nat Rev Urol. 2019 Oct;16(10):599-612. doi: 10.1038/s41585-019-0220-4. Epub 2019 Aug 21. Review.

PMID:
31434998
15.

Combined Next-generation Sequencing and Flow Cytometry Analysis for an Anti-PD-L1 Partial Responder over Time: An Exploration of Mechanisms of PD-L1 Activity and Resistance in Bladder Cancer.

Kates M, Nirschl TR, Baras AS, Sopko NA, Hahn NM, Su X, Zhang J, Kochel CM, Choi W, McConkey DJ, Drake CG, Bivalacqua TJ.

Eur Urol Oncol. 2019 Feb 26. pii: S2588-9311(19)30025-2. doi: 10.1016/j.euo.2019.01.017. [Epub ahead of print]

PMID:
31411999
16.

Predictive biomarkers for drug response in bladder cancer.

Yoshida T, Kates M, Fujita K, Bivalacqua TJ, McConkey DJ.

Int J Urol. 2019 Nov;26(11):1044-1053. doi: 10.1111/iju.14082. Epub 2019 Aug 1. Review.

PMID:
31370109
17.

Editorial Comment.

Kates M.

J Urol. 2019 Oct;202(4):769. doi: 10.1097/01.JU.0000576700.56544.da. Epub 2019 Sep 6. No abstract available.

PMID:
31287762
18.

Contemporary oncologic outcomes of second induction course BCG in patients with nonmuscle invasive bladder cancer.

Daniels MJ, Barry E, Schoenberg M, Lamm DL, Bivalacqua TJ, Sankin A, Kates M.

Urol Oncol. 2020 Jan;38(1):5.e9-5.e16. doi: 10.1016/j.urolonc.2019.05.018. Epub 2019 Jun 27.

PMID:
31255541
19.

Establishing the inter-rater reliability of spinal cord damage manual measurement using magnetic resonance imaging.

Cummins DP, Connor JR, Heller KA, Hubert JS, Kates MJ, Wisniewski KR, Berliner JC, O'Dell DR, Elliott JM, Weber KA 2nd, Smith AC.

Spinal Cord Ser Cases. 2019 Feb 18;5:20. doi: 10.1038/s41394-019-0164-1. eCollection 2019.

20.

Diagnosis of urothelial carcinoma in situ using blue light cystoscopy and the utility of immunohistochemistry in blue light-positive lesions diagnosed as atypical.

Pederzoli F, Murati Amador B, Samarska I, Lombardo KA, Kates M, Bivalacqua TJ, Matoso A.

Hum Pathol. 2019 Aug;90:1-7. doi: 10.1016/j.humpath.2019.04.018. Epub 2019 May 6.

PMID:
31071342
21.

Adjuvant Therapy for Urothelial and Renal Cell Carcinoma.

Patel HD, Kates M, Allaf ME.

Eur Urol Focus. 2020 Jan 15;6(1):3-6. doi: 10.1016/j.euf.2019.04.007. Epub 2019 Apr 26.

PMID:
31031041
22.

Clinical significance of urothelial carcinoma ambiguous for muscularis propria invasion on initial transurethral resection of bladder tumor.

Hassan O, Murati Amador B, Lombardo KA, Salles D, Cuello F, Marwaha AS, Daniels MJ, Kates M, Bivalacqua TJ, Matoso A.

World J Urol. 2020 Feb;38(2):389-395. doi: 10.1007/s00345-019-02782-y. Epub 2019 Apr 27.

PMID:
31030230
23.

Immunotherapy in nonmuscle invasive bladder cancer: current and emerging treatments.

Gupta M, Kates M, Bivalacqua TJ.

Curr Opin Oncol. 2019 May;31(3):183-187. doi: 10.1097/CCO.0000000000000533. Review.

PMID:
30893148
24.

Discovery of VU2957 (Valiglurax): An mGlu4 Positive Allosteric Modulator Evaluated as a Preclinical Candidate for the Treatment of Parkinson's Disease.

Panarese JD, Engers DW, Wu YJ, Bronson JJ, Macor JE, Chun A, Rodriguez AL, Felts AS, Engers JL, Loch MT, Emmitte KA, Castelhano AL, Kates MJ, Nader MA, Jones CK, Blobaum AL, Conn PJ, Niswender CM, Hopkins CR, Lindsley CW.

ACS Med Chem Lett. 2018 Oct 16;10(3):255-260. doi: 10.1021/acsmedchemlett.8b00426. eCollection 2019 Mar 14.

25.

Prognostic implications of prostatic urethral involvement in non-muscle-invasive bladder cancer.

Brant A, Daniels M, Chappidi MR, Joice GA, Sopko NA, Matoso A, Bivalacqua TJ, Kates M.

World J Urol. 2019 Dec;37(12):2683-2689. doi: 10.1007/s00345-019-02673-2. Epub 2019 Mar 8.

PMID:
30850856
26.

Impact of intravesical therapy for non-muscle invasive bladder cancer on the accuracy of urine cytology.

Gupta M, Milbar N, Tema G, Pederzoli F, Chappidi M, Kates M, VandenBussche CJ, Bivalacqua TJ.

World J Urol. 2019 Oct;37(10):2051-2058. doi: 10.1007/s00345-018-02624-3. Epub 2019 Jan 23.

PMID:
30671639
27.

Midsagittal tissue bridges are associated with walking ability in incomplete spinal cord injury: A magnetic resonance imaging case series.

O'Dell DR, Weber KA, Berliner JC, Elliott JM, Connor JR, Cummins DP, Heller KA, Hubert JS, Kates MJ, Mendoza KR, Smith AC.

J Spinal Cord Med. 2020 Mar;43(2):268-271. doi: 10.1080/10790268.2018.1527079. Epub 2018 Oct 22.

28.

CD24 regulates cancer stem cell (CSC)-like traits and a panel of CSC-related molecules serves as a non-invasive urinary biomarker for the detection of bladder cancer.

Ooki A, VandenBussche CJ, Kates M, Hahn NM, Matoso A, McConkey DJ, Bivalacqua TJ, Hoque MO.

Br J Cancer. 2018 Oct;119(8):961-970. doi: 10.1038/s41416-018-0291-7. Epub 2018 Oct 17.

29.

Editorial Comment.

Kates M, Bivalacqua TJ.

J Urol. 2018 Nov;200(5):1011-1012. doi: 10.1016/j.juro.2018.05.157. Epub 2018 Jul 29. No abstract available.

PMID:
30063891
30.

Hospitalisation and readmission costs after radical cystectomy in a nationally representative sample: does urinary reconstruction matter?

Joice GA, Chappidi MR, Patel HD, Kates M, Sopko NA, Stimson CJ, Pierorazio PM, Bivalacqua TJ.

BJU Int. 2018 Dec;122(6):1016-1024. doi: 10.1111/bju.14448. Epub 2018 Jul 26.

31.

Preferences of older adults and their families for Meaningful Use clinical summaries.

Colorafi K, Greenes RA, Kates M.

Mhealth. 2018 Mar 30;4:8. doi: 10.21037/mhealth.2018.03.04. eCollection 2018.

32.

Three-dimensional organoid culture reveals involvement of Wnt/β-catenin pathway in proliferation of bladder cancer cells.

Yoshida T, Sopko NA, Kates M, Liu X, Joice G, McConkey DJ, Bivalacqua TJ.

Oncotarget. 2018 Jan 24;9(13):11060-11070. doi: 10.18632/oncotarget.24308. eCollection 2018 Feb 16.

33.

Characterization of Urothelial Cancer Circulating Tumor Cells with a Novel Selection-Free Method.

Chalfin HJ, Kates M, van der Toom EE, Glavaris S, Verdone JE, Hahn NM, Pienta KJ, Bivalacqua TJ, Gorin MA.

Urology. 2018 May;115:82-86. doi: 10.1016/j.urology.2018.01.036. Epub 2018 Feb 9.

PMID:
29432873
34.

Arsenic promotes the COX2/PGE2-SOX2 axis to increase the malignant stemness properties of urothelial cells.

Ooki A, Begum A, Marchionni L, VandenBussche CJ, Mao S, Kates M, Hoque MO.

Int J Cancer. 2018 Jul 1;143(1):113-126. doi: 10.1002/ijc.31290. Epub 2018 Feb 14.

35.

Comparison of Pathological Stage in Patients Treated with and without Neoadjuvant Chemotherapy for High Risk Upper Tract Urothelial Carcinoma.

Liao RS, Gupta M, Schwen ZR, Patel HD, Kates M, Johnson MH, Hahn NM, McConkey D, Bivalacqua TJ, Pierorazio PM.

J Urol. 2018 Jul;200(1):68-73. doi: 10.1016/j.juro.2017.12.054. Epub 2018 Jan 4.

PMID:
29307680
36.

Ex vivo culture of tumor cells from N-methyl-N-nitrosourea-induced bladder cancer in rats: Development of organoids and an immortalized cell line.

Yoshida T, Kates M, Sopko NA, Liu X, Singh AK, Bishai WR, Joice G, McConkey DJ, Bivalacqua TJ.

Urol Oncol. 2018 Apr;36(4):160.e23-160.e32. doi: 10.1016/j.urolonc.2017.11.024. Epub 2017 Dec 26.

PMID:
29288005
37.

Oncological Outcomes of Sequential Intravesical Gemcitabine and Docetaxel in Patients with Non-Muscle Invasive Bladder Cancer.

Milbar N, Kates M, Chappidi MR, Pederzoli F, Yoshida T, Sankin A, Pierorazio PM, Schoenberg MP, Bivalacqua TJ.

Bladder Cancer. 2017 Oct 27;3(4):293-303. doi: 10.3233/BLC-170126.

38.

Low levels of PSMA expression limit the utility of 18F-DCFPyL PET/CT for imaging urothelial carcinoma.

Campbell SP, Baras AS, Ball MW, Kates M, Hahn NM, Bivalacqua TJ, Johnson MH, Pomper MG, Allaf ME, Rowe SP, Gorin MA.

Ann Nucl Med. 2018 Jan;32(1):69-74. doi: 10.1007/s12149-017-1216-x. Epub 2017 Oct 24.

39.

Hospital Charges and Length of Stay Following Radical Cystectomy in the Enhanced Recovery After Surgery Era.

Semerjian A, Milbar N, Kates M, Gorin MA, Patel HD, Chalfin HJ, Frank SM, Wu CL, Yang WW, Hobson D, Robertson L, Wick E, Schoenberg MP, Pierorazio PM, Johnson MH, Stimson CJ, Bivalacqua TJ.

Urology. 2018 Jan;111:86-91. doi: 10.1016/j.urology.2017.09.010. Epub 2017 Oct 13.

PMID:
29032237
40.

High dose-rate Intra-Operative Radiation Therapy During High Risk Genitourinary Surgery: Initial Observations and a Proposal for its Study in Bladder Cancer.

Kates M, Chappidi MR, Brant A, Milbar N, Sopko NA, Meyer C, Terezakis SA, Herman JM, Efron JE, Safar B, Tran PT, Ahuja N, Pierorazio PM, Bivalacqua TJ.

Bladder Cancer. 2017 Jul 27;3(3):191-199. doi: 10.3233/BLC-170104.

41.

Preclinical Evaluation of Intravesical Cisplatin Nanoparticles for Non-Muscle-Invasive Bladder Cancer.

Kates M, Date A, Yoshida T, Afzal U, Kanvinde P, Babu T, Sopko NA, Matsui H, Hahn NM, McConkey DJ, Baras A, Hanes J, Ensign L, Bivalacqua TJ.

Clin Cancer Res. 2017 Nov 1;23(21):6592-6601. doi: 10.1158/1078-0432.CCR-17-1082. Epub 2017 Aug 14.

42.

Analysis of Hospital Readmissions After Prosthetic Urologic Surgery in the United States: Nationally Representative Estimates of Causes, Costs, and Predictive Factors.

Pederzoli F, Chappidi MR, Collica S, Kates M, Joice GA, Sopko NA, Montorsi F, Salonia A, Bivalacqua TJ.

J Sex Med. 2017 Aug;14(8):1059-1065. doi: 10.1016/j.jsxm.2017.06.003. Epub 2017 Jul 12.

PMID:
28709874
43.

Intravesical BCG Induces CD4+ T-Cell Expansion in an Immune Competent Model of Bladder Cancer.

Kates M, Nirschl T, Sopko NA, Matsui H, Kochel CM, Reis LO, Netto GJ, Hoque MO, Hahn NM, McConkey DJ, Baras AS, Drake CG, Bivalacqua TJ.

Cancer Immunol Res. 2017 Jul;5(7):594-603. doi: 10.1158/2326-6066.CIR-16-0267. Epub 2017 Jun 6.

44.

Erectile Dysfunction Treatment Following Radical Cystoprostatectomy: Analysis of a Nationwide Insurance Claims Database.

Chappidi MR, Kates M, Sopko NA, Joice GA, Tosoian JJ, Pierorazio PM, Bivalacqua TJ.

J Sex Med. 2017 Jun;14(6):810-817. doi: 10.1016/j.jsxm.2017.04.002. Epub 2017 Apr 29.

PMID:
28460994
45.

Evaluation of gender-based disparities in time from initial haematuria presentation to upper tract urothelial carcinoma diagnosis: analysis of a nationwide insurance claims database.

Chappidi MR, Kates M, Tosoian JJ, Johnson MH, Hahn NM, Bivalacqua TJ, Pierorazio PM.

BJU Int. 2017 Sep;120(3):377-386. doi: 10.1111/bju.13878. Epub 2017 May 17.

46.

Oxytocin Reduces Ethanol Self-Administration in Mice.

King CE, Griffin WC, Luderman LN, Kates MM, McGinty JF, Becker HC.

Alcohol Clin Exp Res. 2017 May;41(5):955-964. doi: 10.1111/acer.13359. Epub 2017 Mar 27.

47.

M1 Macrophages Are Predominantly Recruited to the Major Pelvic Ganglion of the Rat Following Cavernous Nerve Injury.

Matsui H, Sopko NA, Hannan JL, Reinhardt AA, Kates M, Yoshida T, Liu X, Castiglione F, Hedlund P, Weyne E, Albersen M, Bivalacqua TJ.

J Sex Med. 2017 Feb;14(2):187-195. doi: 10.1016/j.jsxm.2016.12.012.

48.

Author Reply.

Chappidi MR, Kates M, Bivalacqua TJ.

Urology. 2017 Apr;102:158. doi: 10.1016/j.urology.2016.10.066. Epub 2017 Jan 26. No abstract available.

PMID:
28131434
49.

Assessing Cancer Progression and Stable Disease After Neoadjuvant Chemotherapy for Organ-confined Muscle-invasive Bladder Cancer.

Chappidi MR, Kates M, Brant A, Baras AS, Netto GJ, Pierorazio PM, Hahn NM, Bivalacqua TJ.

Urology. 2017 Apr;102:148-158. doi: 10.1016/j.urology.2016.10.064. Epub 2017 Jan 16.

50.

Mortality trends and the impact of lymphadenectomy on survival for renal cell carcinoma patients with distant metastasis.

Patel HD, Gorin MA, Gupta N, Kates M, Johnson MH, Pierorazio PM, Allaf ME.

Can Urol Assoc J. 2016 Nov-Dec;10(11-12):389-395. doi: 10.5489/cuaj.1999.

Supplemental Content

Support Center